Keywords: ceplene, shows, long-term, activity, hcv, maxim, pharmaceuticals
Ceplene shows long-term activity in HCV
Article | 24 April 2001
Maxim Pharmaceuticals has announced positive results in its 72-weekPhase II study evaluating Ceplene (histamine dihydrochloride) plus interferon alfa in treatment-naive, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
